Trial record 1 of 1 for:
MORAb-004-203-STS
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation (SOURCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01574716 |
|
Recruitment Status :
Completed
First Posted : April 10, 2012
Results First Posted : August 21, 2019
Last Update Posted : August 21, 2019
|
Sponsor:
Morphotek
Information provided by (Responsible Party):
Morphotek
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metastatic Soft Tissue Sarcoma | Drug: MORAb-004 Drug: Gemcitabine Drug: Docetaxel Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 209 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel With MORAb-004 in Metastatic Soft Tissue Sarcoma |
| Actual Study Start Date : | August 7, 2012 |
| Actual Primary Completion Date : | August 11, 2015 |
| Actual Study Completion Date : | August 2, 2016 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Soft Tissue Sarcoma
| Arm | Intervention/treatment |
|---|---|
| Experimental: MORAb-004, gemcitabine, docetaxel |
Drug: MORAb-004
IV, Days 1 and 8 of every cycle until disease progression Drug: Gemcitabine IV, Days 1 and 8 of each cycle until disease progression Drug: Docetaxel IV, Day 8 of every cycle until disease progression |
| Active Comparator: Placebo, gemcitabine, docetaxel |
Drug: Gemcitabine
IV, Days 1 and 8 of each cycle until disease progression Drug: Docetaxel IV, Day 8 of every cycle until disease progression Drug: Placebo |
Primary Outcome Measures :
- Part 2: Radiologic Progression-free Survival (PFS) [ Time Frame: From date of first dose until date of first observation of disease progression, or death due to any cause (up to approximately 3 years) ]PFS was defined as the time (in weeks) from the date of randomization to the date of first observation of disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or date of death, regardless of the cause.
Secondary Outcome Measures :
- Part 2: Symptomatic Progression-free Survival [ Time Frame: From date of first dose until date of first observation of disease progression, symptomatic progression, or death due to any cause (up to approximately 3 years) ]PFS including symptomatic progression was defined as the time (in weeks) from the date of randomization to the date of the first observation of disease progression according to RECIST 1.1, symptomatic progression, or death due to any cause.
- Part 2: Overall Survival (OS) [ Time Frame: From date of first dose until date of death from any cause (up to approximately 3.5 years) ]OS was defined as the time (in months) from the date of randomization to the date of death, regardless of the cause.
- Part 2: Overall Response Rate (ORR) [ Time Frame: From date of first dose until disease progression (up to approximately 3.5 years) ]ORR was defined as the percentage of subjects with either a complete response (CR) or a partial response (PR) based on RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.
- Part 2: Radiologic Progression-free Survival Rate (PFR) [ Time Frame: Weeks 12, 24, 48 and 52 ]Radiologic progression-free survival rate was defined as the percentage of subjects achieving radiologic PFS at the pre-specified time points.
- Part 2: Number of Participants Who Had Relationship Between MORAb-004 Exposures and Biomarker Levels [ Time Frame: Up to approximately 3 years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Be at least 18 years of age
- Be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period
- Have a histologically confirmed diagnosis of mSTS as defined by the 4 specified study subgrouped
- Have been treated in the metastatic setting with 0 to 2 prior systemic regimens for mSTS (Systemic treatment regimens given in the neoadjuvant setting and maintenance therapies will not be considered as regimens in the metastatic setting for the purposes of this protocol. Prior anthracycline-based regimen is allowable but not required. Subjects with extra-skeletal small round blue cell sarcomas, including rhabdomyosarcomas, must have exhausted or be intolerant of standard first line anthracycline-based chemotherapy.)
- Have measurable disease, as defined by RECIST v 1.1 assess within 2 weeks of study entry and have radiologically documented disease progression greater than or equal to a 10% increase in the sum of the longest diameters of target lesions present within 6 months prior to randomization
- Have tumor tissue available for TEM-1 biomarker studies
- Be willing and able to provide written informed consent
Exclusion Criteria:
- Have received more than 2 prior systemic treatment regimens for mSTS
- Have received either gemcitabine or docetaxel in any previous treatment for mSTS (regardless of the line of treatment)
- Have a diagnosis of primary bone sarcoma of any histological type.
- Have a history of clinically significant heart disease, or clinically significant arrhythmia on ECG within the past 6 months
- Have a history of allergic reaction to prior monoclonal antibody or biologic agent
- Have received previous treatment with MORAb-004 (anti-TEM-1)
- Have a medical condition with a high risk of bleeding (e.g., a known bleeding disorder, a coagulopathy, or a tumor that involves the major vessels) or have a recent (within past 6 months) history of a significant bleeding event
- Have undergone major surgical procedures or open biopsy, have significant traumatic injury within 30 days prior to the first date of study treatment, or have major surgical procedures anticipated during the study
- Have a serious non-healing wound, an ulcer (including gastrointestinal), or a bone fracture
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01574716
Locations
Show 29 study locations
Sponsors and Collaborators
Morphotek
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Morphotek |
| ClinicalTrials.gov Identifier: | NCT01574716 |
| Other Study ID Numbers: |
MORAb-004-203-STS 2012-001399-12 ( EudraCT Number ) |
| First Posted: | April 10, 2012 Key Record Dates |
| Results First Posted: | August 21, 2019 |
| Last Update Posted: | August 21, 2019 |
| Last Verified: | November 2016 |
Additional relevant MeSH terms:
|
Sarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Gemcitabine Docetaxel Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Tubulin Modulators Antimitotic Agents Mitosis Modulators |